NeuBase Therapeutics, Inc.
Company Snapshot: NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc., a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
- Mar 26 2020 NeuBase Therapeutics Reports Financial Results for the First Fiscal Quarter of 2020
- Feb 21 2020 NeuBase Therapeutics Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
- Jan 9 2020 NeuBase Therapeutics Reports Financial Results for Fiscal Year 2019
- Dec 2 2019 NeuBase Therapeutics Wins The Scientist’s Top 10 Innovations of 2019 Award for its Janus Base Technology